Advertisement

Inflammation Research

, Volume 67, Issue 11–12, pp 927–936 | Cite as

LncRNA MEG3 impacts proliferation, invasion, and migration of ovarian cancer cells through regulating PTEN

  • Juelan Wang
  • Wenqian Xu
  • Yangke He
  • Qi Xia
  • Siwei Liu
Original Research Paper

Abstract

Objective and design

We investigated the expressions of lncRNA MEG3 and PTEN in ovarian cancer tissues and their effects on cell proliferation, cycle and apoptosis of ovarian cancer.

Methods

Expression levels of MEG3 in ovarian cancer cell lines and normal ovarian cell lines were detected by qRT-PCR. Cell viability was detected by MTT assay. Cell apoptosis and cell cycle distribution were measured by flow cytometry. Cell invasion capability was tested by transwell assay. Cell migration capacity was tested by wound healing. The xenograft model was constructed to explore the effect of lncRNA MEG3 on ovarian cancer in vivo.

Result

Compared with normal ovarian cells, expression levels of MEG3 and PTEN were relatively lower in ovarian cancer cells. There was a positive correlation between the expression of PTEN and the expression of MEG3. Enhanced expression level of PTEN suppressed SKOV3 cell proliferation, increased cell apoptosis rate, and decreased cell invasion and migration.

Conclusion

LncRNA MEG3 and PTEN were down-regulated in ovarian cancer cells. LncRNA MEG3 regulated the downstream gene PTEN in ovarian cancer cells to prohibit cell proliferation, promote apoptosis and block cell cycle progression.

Keywords

Ovarian cancer LncRNA MEG3 PTEN 

Abbreviations

ANOVA

Analysis of variance

lncRNAs

Long non-coding RNAs

MEG3

Maternally expressed 3 gene

nt

Nucleotides

PI3K

Phosphatidylinositol-3-kinase

Notes

Authors’ contributions

JW and WX: critical revision of the manuscript; YH and QX: substantial contribution to the conception and design of the work, and manuscript drafting; QX and YH: acquisition, analysis, and interpretation of the data; SL: revising the manuscript critically and final approval of the version to be published. All authors have read and approved the final article.

Compliance with ethical standards

Conflict of interest

The authors confirm that there are no conflicts of interest.

Ethical approval

All procedures performed in studies involving animals were in accordance with the ethical standards of Sichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospital and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

References

  1. 1.
    Bruney L, Liu Y, Grisoli A, Ravosa MJ, Stack MS. Integrin-linked kinase activity modulates the pro-metastatic behavior of ovarian cancer cells. Oncotarget. 2016;7:21968–81.CrossRefGoogle Scholar
  2. 2.
    Itamochi H. Targeted therapies in epithelial ovarian cancer: Molecular mechanisms of action. World J Biol Chem. 2010;1:209–20.CrossRefGoogle Scholar
  3. 3.
    Gibb EA, Brown CJ, Lam WL. The functional role of long non-coding RNA in human carcinomas. Mol Cancer. 2011;10:38.CrossRefGoogle Scholar
  4. 4.
    Yu X, Li Z. Long non-coding RNA HOTAIR: a novel oncogene (review). Mol Med Rep. 2015;12:5611–8.CrossRefGoogle Scholar
  5. 5.
    Meseure D, Drak Alsibai K, Nicolas A, Bieche I, Morillon A. long noncoding RNAs as new architects in cancer epigenetics, prognostic biomarkers, and potential therapeutic targets. Biomed Res Int 2015; 2015:320214.CrossRefGoogle Scholar
  6. 6.
    Cui L, Xie XY, Wang H, Chen XL, Liu SL, Hu LN. Expression of long non-coding RNA HOTAIR mRNA in ovarian cancer. Sichuan Da Xue Xue Bao Yi Xue Ban. 2013;44:57–9.PubMedGoogle Scholar
  7. 7.
    Yang SL, Lin RX, Si LH, Cui MH, Zhang XW, Fan LM. Expression and functional role of long non-coding RNA AFAP1-AS1 in ovarian cancer. Eur Rev Med Pharmacol Sci. 2016;20:5107–12.PubMedGoogle Scholar
  8. 8.
    Miyoshi N, Wagatsuma H, Wakana S, Shiroishi T, Nomura M, Aisaka K, et al. Identification of an imprinted gene, Meg3/Gtl2 and its human homologue MEG3, first mapped on mouse distal chromosome 12 and human chromosome 14q. Genes Cells. 2000;5:211–20.CrossRefGoogle Scholar
  9. 9.
    Sun L, Li Y, Yang B. Downregulated long non-coding RNA MEG3 in breast cancer regulates proliferation, migration and invasion by depending on p53’s transcriptional activity. Biochem Biophys Res Commun. 2016;478:323–9.CrossRefGoogle Scholar
  10. 10.
    Qin R, Chen Z, Ding Y, Hao J, Hu J, Guo F. Long non-coding RNA MEG3 inhibits the proliferation of cervical carcinoma cells through the induction of cell cycle arrest and apoptosis. Neoplasma. 2013;60:486–92.CrossRefGoogle Scholar
  11. 11.
    Sun M, Xia R, Jin F, Xu T, Liu Z, De W, et al. Downregulated long noncoding RNA MEG3 is associated with poor prognosis and promotes cell proliferation in gastric cancer. Tumour Biol. 2014;35:1065–73.CrossRefGoogle Scholar
  12. 12.
    Yin DD, Liu ZJ, Zhang E, Kong R, Zhang ZH, Guo RH. Decreased expression of long noncoding RNA MEG3 affects cell proliferation and predicts a poor prognosis in patients with colorectal cancer. Tumour Biol. 2015;36:4851–9.CrossRefGoogle Scholar
  13. 13.
    Lu KH, Li W, Liu XH, Sun M, Zhang ML, Wu WQ, et al. Long non-coding RNA MEG3 inhibits NSCLC cells proliferation and induces apoptosis by affecting p53 expression. BMC Cancer. 2013;13:461.CrossRefGoogle Scholar
  14. 14.
    Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997;275:1943–7.CrossRefGoogle Scholar
  15. 15.
    Yamada KM, Araki M. Tumor suppressor PTEN: modulator of cell signaling, growth, migration and apoptosis. J Cell Sci. 2001;114:2375–82.PubMedGoogle Scholar
  16. 16.
    Di Cristofano A, Pandolfi PP. The multiple roles of PTEN in tumor suppression. Cell. 2000;100:387–90.CrossRefGoogle Scholar
  17. 17.
    Goberdhan DC, Wilson C. PTEN: tumour suppressor, multifunctional growth regulator and more. Hum Mol Genet. 2003;2:R239–R248 (12 Spec No).CrossRefGoogle Scholar
  18. 18.
    Mutter GL, Lin MC, Fitzgerald JT, Kum JB, Baak JP, Lees JA, et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst. 2000;92:924–30.CrossRefGoogle Scholar
  19. 19.
    Zhang J, Yao T, Wang Y, Yu J, Liu Y, Lin Z. Long noncoding RNA MEG3 is downregulated in cervical cancer and affects cell proliferation and apoptosis by regulating miR-21. Cancer Biol Ther. 2016;17:104–13.CrossRefGoogle Scholar
  20. 20.
    Zhang CY, Yu MS, Li X, Zhang Z, Han CR, Yan B. Overexpression of long non-coding RNA MEG3 suppresses breast cancer cell proliferation, invasion, and angiogenesis through AKT pathway. Tumour Biol. 2017;39:1010428317701311.PubMedGoogle Scholar
  21. 21.
    Wu XS, Wang XA, Wu WG, Hu YP, Li ML, Ding Q, et al. MALAT1 promotes the proliferation and metastasis of gallbladder cancer cells by activating the ERK/MAPK pathway. Cancer Biol Ther. 2014;15:806–14.CrossRefGoogle Scholar
  22. 22.
    Xiu YL, Sun KX, Chen X, Chen S, Zhao Y, Guo QG, et al. Upregulation of the lncRNA Meg3 induces autophagy to inhibit tumorigenesis and progression of epithelial ovarian carcinoma by regulating activity of ATG3. Oncotarget. 2017;8:31714–25.PubMedPubMedCentralGoogle Scholar
  23. 23.
    Sheng X, Li J, Yang L, Chen Z, Zhao Q, Tan L, et al. Promoter hypermethylation influences the suppressive role of maternally expressed 3, a long non-coding RNA, in the development of epithelial ovarian cancer. Oncol Rep. 2014;32:277–85.CrossRefGoogle Scholar
  24. 24.
    Zhang J, Liu J, Xu X, Li L. Curcumin suppresses cisplatin resistance development partly via modulating extracellular vesicle-mediated transfer of MEG3 and miR-214 in ovarian cancer. Cancer Chemother Pharmacol. 2017;79:479–87.CrossRefGoogle Scholar
  25. 25.
    Tanwar PS, Kaneko-Tarui T, Lee HJ, Zhang L, Teixeira JM. PTEN loss and HOXA10 expression are associated with ovarian endometrioid adenocarcinoma differentiation and progression. Carcinogenesis. 2013;34:893–901.CrossRefGoogle Scholar
  26. 26.
    Martins FC, Santiago I, Trinh A, Xian J, Guo A, Sayal K, et al. Combined image and genomic analysis of high-grade serous ovarian cancer reveals PTEN loss as a common driver event and prognostic classifier. Genome Biol. 2014;15:526.CrossRefGoogle Scholar
  27. 27.
    Shen W, Li HL, Liu L, Cheng JX. Expression levels of PTEN, HIF-1alpha, and VEGF as prognostic factors in ovarian cancer. Eur Rev Med Pharmacol Sci. 2017;21:2596–603.PubMedGoogle Scholar
  28. 28.
    Wang L, Wang C, Jin S, Qu D, Ying H. Expression of NF-kappaB and PTEN in primary epithelial ovarian carcinoma and the correlation with chemoresistance. Int J Clin Exp Pathol. 2015;8:10953–63.PubMedPubMedCentralGoogle Scholar
  29. 29.
    Tanwar PS, Mohapatra G, Chiang S, Engler DA, Zhang L, Kaneko-Tarui T, et al. Loss of LKB1 and PTEN tumor suppressor genes in the ovarian surface epithelium induces papillary serous ovarian cancer. Carcinogenesis. 2014;35:546–53.CrossRefGoogle Scholar
  30. 30.
    Li J, Hu K, Gong G, Zhu D, Wang Y, Liu H, et al. Upregulation of MiR-205 transcriptionally suppresses SMAD4 and PTEN and contributes to human ovarian cancer progression. Sci Rep. 2017;7:41330.CrossRefGoogle Scholar
  31. 31.
    Liu H, Pan Y, Han X, Liu J, Li R. MicroRNA-216a promotes the metastasis and epithelial-mesenchymal transition of ovarian cancer by suppressing the PTEN/AKT pathway. Onco Targets Ther. 2017;10:2701–9.CrossRefGoogle Scholar
  32. 32.
    Fang Y, Xu C, Fu Y. MicroRNA-17-5p induces drug resistance and invasion of ovarian carcinoma cells by targeting PTEN signaling. J Biol Res (Thessalon). 2015;22:12.CrossRefGoogle Scholar
  33. 33.
    Yang NQ, Luo XJ, Zhang J, Wang GM, Guo JM. Crosstalk between Meg3 and miR-1297 regulates growth of testicular germ cell tumor through PTEN/PI3K/AKT pathway. Am J Transl Res. 2016;8:1091–9.PubMedPubMedCentralGoogle Scholar
  34. 34.
    Liu Z, Ren YA, Pangas SA, Adams J, Zhou W, Castrillon DH, et al. FOXO1/3 and PTEN Depletion in Granulosa Cells Promotes Ovarian Granulosa Cell Tumor Development. Mol Endocrinol. 2015;29:1006–24.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  1. 1.Department of OncologySichuan Academy of Medical Sciences and Sichuan Provincial People’s HospitalChengduChina
  2. 2.Department of Cardiology, Daping HospitalThe Third Military Medical UniversityChongqingChina
  3. 3.Department of Obstetrics and GynecologySichuan Academy of Medical Sciences and Sichuan Provincial People’s HospitalChengduChina

Personalised recommendations